Raphael Pharmaceutical (RAPH) Return on Equity (2021 - 2025)

Raphael Pharmaceutical has disclosed Return on Equity across 5 years of filings, most recently posting 0.0% for Q3 2025.

• Return on Equity for Q3 2025 came in at 0.0%, down 2.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 0.0% (down 2.0% YoY), and the FY2025 annual result was 0.01%, down 4.0% from the prior year.
• Return on Equity came in at 0.0% for Q3 2025 at Raphael Pharmaceutical, down from 0.01% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.92% in Q2 2023 to a low of 10.86% in Q4 2021.
• The 5-year median for Return on Equity is 0.07% (2022), against an average of 1.21%.
• Across the five-year window, Return on Equity soared 935 bps in 2022 and tumbled 710 bps in 2024, its largest moves.
• Raphael Pharmaceutical's Return on Equity stood at 10.86% in 2021, then surged by 86 bps to 1.51% in 2022, then soared by 47 bps to 0.8% in 2023, then surged by 103 bps to 0.02% in 2024, then tumbled by 85 bps to 0.0% in 2025.
• The last three Return on Equity figures came in at 0.0% (Q3 2025), 0.01% (Q2 2025), and 0.01% (Q1 2025), per Business Quant data.